Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral tablet for oral use. It is employed as an adjunct therapy to control partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency.

GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under EU GMP guidelines and undergo rigorous quality testing before distribution. The product is packaged in tamper‑evident blister packs to ensure integrity during transport.

Lacosamide is indicated as an adjunctive treatment for focal (partial‑onset) seizures in epilepsy, targeting patients who continue to experience seizures despite other therapies. - Partial‑onset seizures in adults: Reduces seizure frequency when added to existing antiepileptic regimens. - Partial‑onset seizures in children (≥4 years): Provides adjunctive control of seizures in pediatric patients when other agents are insufficient. - Focal epilepsy refractory to monotherapy: Enhances overall seizure management as part of combination therapy.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness that may affect balance. - Nausea: feeling of queasiness, sometimes accompanied by vomiting or loss of appetite. - Headache: mild to moderate pain or pressure in the head, often worsened by stress. - Fatigue: unusual tiredness or lack of energy that can interfere with daily activities.

Serious or Rare Side Effects: - Suicidal thoughts or behavior: emergence of depressive symptoms, mood changes, or urges to self‑harm requiring immediate medical attention. - Severe skin reactions such as Stevens‑Johnson syndrome: painful rash with blistering, mucosal involvement, and potential skin detachment. - Cardiac arrhythmias, including PR‑interval prolongation: abnormal heart rhythm detectable on ECG, which may cause palpitations or fainting.

When prescribing lacosamide, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose based on creatinine clearance to avoid accumulation. - Hepatic impairment: monitor liver function and consider dose reduction in moderate to severe disease. - Cardiac conduction: obtain baseline ECG and monitor for PR‑interval prolongation during therapy. - Concomitant CNS depressants: use caution as combined effects may increase dizziness or somnolence. - Abrupt discontinuation: taper gradually to reduce risk of seizure recurrence. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its plasma concentration or enhancing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacosamide levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampicin): may lower lacosamide concentrations, reducing efficacy. - Other sodium channel blockers (e.g., oxcarbazepine, lamotrigine): additive CNS depression and cardiac effects. - QT‑prolonging agents (e.g., certain antiarrhythmics): may exacerbate cardiac conduction abnormalities. - Alcohol: concurrent use can enhance dizziness and sedation.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring due to potential interaction. - Oral contraceptives: efficacy may be slightly reduced; advise alternative contraception if needed. - Antihypertensives: monitor blood pressure as additive hypotensive effect possible.